Abstract 5147
Background
Patient rights has been developed from human rights. Human rights emerged from the Universal Declaration of Human Rights. The Declaration is a milestone document in the history of human rights (1). Today the patient’s rights have become an important issue on the political agenda. Individual’s awareness of their own rights in the health area is constantly increasing. Patient’s rights are becoming primary concern in improving quality of health care (2). Today the patient becomes the consumer (3). The most important role that nurses have is delivering quality care for the patients and also act as patient advocates. Nurses must understand the importance of patient rights. The main aim of the survey is to analyze, investigate, compare and present, the legal framework of the patient’s rights legislation in the European Union.
Methods
A literature search and review related to the patient right was conducted using PubMed, Cinahl, Medline and Google Scholar. With descriptive method we set up a theoretical framework of the patient’s rights legislation. We also use comporative method to discover the similarities and differences between legal systems and their components.
Results
Patient’s rights are in thirteen European Member States regulated by specific law - Law on patient’s rights.
Conclusions
EU Member States do not have a common legislation for patient’s rights. Patient’s rights vary from country to country. Some countries have a single law or act, others use multiple pieces of legislation. Nurses are an important voice of the patient. References: 1. Universal Declaration of Human Rights. Avalible at: Https://www.un.org/en/universal-declaration-human-rights/ (10. 4. 2019). 2. Opinion of the European Economic and Social Committee on Patients’ rights. Official Journal EU, C10/67. Avalible at: Https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2008:010:0067:0071:EN:PDF (10. 4. 2019). 3. OECD - Patients, Patient Organisations and the Production of Medical Science and Technology. Avalible at: Http://www.oecd.org/education/innovation-education/32126031.pdf (10. 4. 2019). 4. Kozuh M., 2016. Legal Arrangements for the Protection of Patients’ Rights: A Comparative Overview of the Regulation in the EU (Master Thesis). University of Primorska Slovenia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Maja Kozuh.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1945 - Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies.
Presenter: Christoph Heilig
Session: Poster Display session 3
Resources:
Abstract
3021 - Homogenisation of Leftover Surgical Tissue across multiple cancer types: a Feasibility Study (HoLST-F)
Presenter: Lavinia Spain
Session: Poster Display session 3
Resources:
Abstract
2882 - Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumors: updated results from ILLUMINATE-101
Presenter: Hani Babiker
Session: Poster Display session 3
Resources:
Abstract
1950 - Phase 1 Dose Escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumors: Updated results
Presenter: Erkut Borazanci
Session: Poster Display session 3
Resources:
Abstract
2391 - A phase 1 study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Anna Spreafico
Session: Poster Display session 3
Resources:
Abstract
5692 - FPA150 (B7-H4 antibody) Phase 1 Update in Advanced Solid Tumors: Monotherapy and in Combination with Pembrolizumab
Presenter: Zev Wainberg
Session: Poster Display session 3
Resources:
Abstract
2416 - MG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients
Presenter: Eun Hee Lee
Session: Poster Display session 3
Resources:
Abstract
2661 - Tumor stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumors.
Presenter: Myriam Fabre
Session: Poster Display session 3
Resources:
Abstract
3681 - Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Presenter: May Cho
Session: Poster Display session 3
Resources:
Abstract
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract